Alpha Tau Medical (DRTS) CFO Raphi Levy Sells $240K of Stock

Multiple Scheduled Stock Sales by CFO Raphi Levy

Alpha Tau Medical Ltd. (NASDAQ: DRTS) Chief Financial Officer Raphi Levy executed a planned sale of 20,000 shares of company stock on June 30, 2026, according to SEC documentation. The transaction was completed at a price of $12.00 per share, representing a total transaction value of $240,000. The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, which allows corporate insiders to set up a predetermined schedule to sell shares over time.

This transaction represents a significant block of shares for a company of Alpha Tau Medical's size, and it is part of a broader pattern of selling by the Chief Financial Officer. It stands as Levy's fourth scheduled trade during the month of June 2026, illustrating a systematic reduction in his personal holdings over a short period.

CFO's Active June Sales Campaign

Prior to this latest transaction, Levy completed several other planned trades. On June 25, 2026, he sold 20,000 shares of stock at $11.00 per share, totaling $220,000. Just two days before that, on June 23, 2026, Levy completed two separate sales of 17,500 shares each, both executed at a price of $9.55 per share, with each of those trades valued at $167,049.75. All of these transactions were established under pre-arranged trading plans, which are commonly used by executives to avoid concerns about trading on material, non-public information.

Alpha Tau Medical Stock Performance

Alpha Tau Medical shares closed at $15.24 on the day prior to the latest transaction, and the stock was trading around $12.40 on Wednesday. The medical technology company currently has a market capitalization of $1.40 billion. Over the past year, the share price has ranged from a low point of $3.43 to a high point of $15.79. The stock is currently trading above its 200-day moving average of $9.34, though it remains slightly below its shorter-term 50-day moving average of $13.76.

Wall Street Analysts Stand Behind the Tech

Despite the recurring insider sales, Wall Street analysts have maintained an optimistic outlook on Alpha Tau Medical. On September 3, 2026, Barclays maintained its Overweight rating on the stock and raised its price target to $30.00 from a previous target of $17.00.

Prior to that, HC Wainwright & Co. updated its views several times. The firm maintained a Buy rating and lifted its target to $16.00 from $15.00 on August 11, 2026. This followed reiterations of their Buy rating with a $15.00 price target on both July 22, 2026, and July 16, 2026. Across the five analysts covering the stock, the consensus recommendation remains a buy, with an average target price of $17.80.

About Alpha Tau Medical

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company based in Jerusalem, Israel. The company focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy, known as Alpha DaRT, to treat solid cancers. The technology is currently undergoing clinical trials for various solid tumors, including skin, oral, pancreatic, prostate, lung, liver, and breast cancers. Because the company is still in the clinical-development phase and has not yet achieved commercial profitability, it reported an loss per share of -$1.04 and does not have a meaningful P/E ratio.

What to Watch at Alpha Tau Medical Ltd.

Investors monitoring Alpha Tau Medical will want to watch for the company's next earnings report, which is scheduled for November 19, 2026. Future SEC filings will reveal whether the CFO's scheduled sales program continues into the second half of the year, or if other corporate insiders begin executing similar trading plans. While insider sales can occur for many personal financial reasons, a sustained pattern of selling by a Chief Financial Officer often draws close scrutiny from the market.